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 25 
All bacterial infections occur within a polymicrobial environment, from which a pathogen 26 
population emerges to establish disease within a host. Emphasis has been placed on 27 
prevention of pathogen dominance by competing microflora acting as probiotics1. Here we 28 
show that virulence of the human pathogen, Staphylococcus aureus is augmented by native, 29 
 2 
polymicrobial, commensal skin flora and individual species actŝŶŐĂƐ  ?ƉƌŽŝŶĨĞĐƚŝŽƵƐĂŐĞŶƚƐ ? ? 30 
The outcome is pathogen proliferation but not commensal. Pathogenesis augmentation can be 31 
mediated by particulate cell wall peptidoglycan (PGN), reducing the S. aureus infectious dose 32 
by over 1000-fold. This phenomenon occurs using a range of S. aureus strains, infection models 33 
and is not mediated by established receptor-mediated pathways including Nod1, Nod2, Myd88 34 
and the NLPR3 inflammasome. During mouse sepsis, augmentation depends on liver resident 35 
macrophages (Kupffer cells, KC), that ĐĂƉƚƵƌĞĂŶĚŝŶƚĞƌŶĂůŝƐĞďŽƚŚƉĂƚŚŽŐĞŶĂŶĚ ?ƉƌŽŝnfectious 36 
ĂŐĞŶƚ ? ?leading to reduced production of reactive oxygen species, pathogen survival and 37 
subsequent multiple liver abscess formation. The augmented infection model more closely 38 
resembles the natural situation and establishes the role of resident environmental microflora 39 
in initiation of disease by an invading pathogen. As human microflora is ubiquitous2 its role in 40 
increasing susceptibility to infection S. aureus highlights potential strategies for disease 41 
prevention.  42 
 43 
Whilst S. aureus exists as part of a heterogeneous resident microflora3, it often emerges as an 44 
invasive human pathogen, capable of in vivo persistence and dissemination4. The surrounding 45 
commensal community is protective in some contexts5,6, while in others coinfection can be 46 
mutually beneficial for pathogen and commensal7. During pathogenesis, the population of S. 47 
aureus expands clonally, as individual organisms within the original infecting cohort found the 48 
characteristic abscesses8,9. As animal host mortality is dose dependent10, most of the inoculum 49 
does not directly contribute to disease. We hypothesised that virulence might be enhanced by 50 
co-inoculation with non-infectious organisms. To test this, we first used the established zebrafish 51 
embryo infection model10 and demonstrated that a virulence attenuated mutant (pheP saeR; 52 
deficient in an amino acid permease and a global regulator of virulence factors10,11) of S. aureus 53 
SH1000 is able to augment infection caused by low dose of a virulent strain (Fig. 1a). Only the low 54 
dose virulent organism substantially benefits (Supplementary Data Fig. 1a). To test if unrelated 55 
non-pathogenic organisms can similarly augment infection, the skin commensal M. luteus was 56 
co-injected with S. aureus (Fig. 1b). M. luteus alone does not cause disease and is swiftly 57 
eliminated from the host when injected alone or in combination with S. aureus (Fig. 1c, 58 
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Supplementary Data Fig. 1b). However, its presence significantly enhances S. aureus virulence 59 
leading to host mortality and pathogen proliferation. Both pathogen and commensal can be 60 
found co-localised in phagocytes in vivo (Fig. 1d), characteristic of S. aureus infection dynamics 61 
in this model.  62 
 63 
S. aureus infection of humans is often iatrogenic, resulting in co-inoculation of skin (or other) 64 
microflora. The ability of human skin commensal organisms to augment S. aureus mammalian 65 
infection was next tested.  1-2 x 108 CFU S. epidermidis or M. luteus led to augmentation (Fig. 1e-66 
h). Survival of S. epidermidis was not enhanced by S. aureus, and M. luteus was completely 67 
cleared (Fig. 1f). 1 x 108 CFU M. luteus could augment as low as 1 x 105 CFU S. aureus 68 
(Supplementary data Fig. 1c). Combining 1 x 106 CFU of both S. aureus and M. luteus gave a 69 
significant increase in S. aureus liver CFU (Supplementary data Fig. 1d). Live commensal flora, 70 
whilst able to augment infection are cleared by the host, likely because they do not have the 71 
multiple mechanisms that enable S. aureus to avoid killing by the innate immune system12,13. The 72 
number of commensal bacteria necessary to augment S. aureus infection is comparable to that 73 
found on the skin, where punch biopsies have demonstrated at least 106 CFU/cm2 14. Also in a 74 
study of vascular catheters, a range of bacteria were found with numbers up to 107 CFU15. 75 
However, it was important to demonstrate the ability of the natural mix of mammalian skin 76 
microflora to augment pathogenesis. Thus, skin-associated, microbiota containing material from 77 
either naturally colonised or GF mice was harvested and used directly to augment S. aureus 78 
infection.  Pathogenesis of S. aureus could be augmented by material from mice colonised with 79 
native microflora, whereas material from GF mice could not (Fig. 1i, P<0.05).  This demonstrates 80 
that native flora has the capacity to augment S. aureus infection.  Given the varied molecular 81 
ŵŽŝĞƚŝĞƐƚŚĂƚĐĂŶĂƵŐŵĞŶƚŝŶĨĞĐƚŝŽŶ ?ǁĞŚĂǀĞŶĂŵĞĚƚŚĞŵ “ƉƌŽŝŶĨĞĐƚŝŽƵƐĂŐĞŶƚƐ ? ? 82 
 83 
dŽĚĞƚĞƌŵŝŶĞƚŚĞŵŽůĞĐƵůĂƌďĂƐŝƐŽĨ “ƉƌŽŝŶĨĞĐƚŝŽƵƐĂŐĞŶƚƐ ?ǁĞĨŝƌƐƚĞƐƚĂďůŝƐŚĞĚƚŚĂƚŚĞĂƚŬŝůůĞĚ84 
M. luteus can augment zebrafish infection, strongly suggesting a bacterial cellular component 85 
may be responsible (Fig. 1b). Peptidoglycan (PGN) is a bacterial cell wall polymer, known to have 86 
many host immune system interactions16,17. Particulate, but not soluble, M. luteus PGN can 87 
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augment infection and is co-localised within phagocytes with S. aureus (Fig. 2a, b, c, 88 
Supplementary Data Fig. 1e). Latex beads are also co-phagocytosed but do not alter infection 89 
dynamics or outcome (Supplementary Data Fig. 1f-i, Supplementary video 5), demonstrating this 90 
is not a simple niche-filling phenomenon.  PGN as a proinfectious agent was then tested in the 91 
murine sepsis model of infection, where a mixed inoculum consisting of S. aureus NewHG (low 92 
dose, 1x106 CFU) and M. luteus PGN  ? ? ? ?ʅŐ ? were injected intravenously, compared to each 93 
component alone. PGN alone had no effect on animal weight or health status (Supplementary 94 
Fig. 2a). Mice receiving the mixed inoculum lost significantly more weight than low dose controls 95 
(P<0.001), with exceedingly high S. aureus numbers (around 108 CFU) recovered from livers (Fig. 96 
2d, e). Only mixed inocula caused severe structural deterioration of liver parenchyma including 97 
multiple, small abscesses (Fig. 2f). At 72 hours post infection (hpi), in the presence of PGN, 98 
classical abscesses were formed where a central extracellular nidus of S. aureus is surrounded by 99 
a dense neutrophilic infiltrate. Solubilised PGN and latex beads did not augment infection (Fig. 100 
2d, e, Supplementary Data Fig. 2b-d). PGN augmented infection with the community acquired 101 
MRSA strain JE2 (Supplementary Data Fig. 2e-g), leading to increased kidney CFU and weight loss. 102 
As the augmentation phenomenon has been demonstrated with three distinct strains, ranging 103 
from laboratory to emergent clinical epidemic strains18, and including both methicillin sensitive 104 
(MSSA) and methicillin resistant strains (MRSA), it is inferred that strain specificity does not play 105 
a significant role. 106 
 107 
Large inocula are required to reliably establish infection in S. aureus murine models, with 107-8 108 
CFU injected as standard19 ?21. It is improbable that such large doses are mirrored in human 109 
ŝŶĨĞĐƚŝŽŶĂŶĚĞĂƌůǇǁŽƌŬŶŽƚĞƐƚŚĂƚ ‘ĂŶĂƐĂůĚƌŽƉůĞƚŽĨ ? ? ?ʅŵĚŝĂŵĞƚĞƌĐŽƵůĚŶŽƚĂĐĐŽŵŵŽĚĂƚĞ110 
this number, even if it consisted entirely of staphylococci22. However, the S. aureus infectious 111 
dose can be drastically reduced when augmented with PGN. Significant weight loss occurred with 112 
a dose of S. aureus as low as 1x105 CFU in the co-inoculum (Supplementary Data Fig. 2h) and 113 
strikingly, high liver bacterial numbers were recovered from all mice receiving 1x104 CFU (Fig. 114 
2g). Astonishingly, one mouse exhibited a liver burden of 106 CFU with an inoculum of only 700 115 
CFU. A lower PGN dose of 250 ʅg also augmented (Fig 2h, Supplementary Data Fig. 2a).  116 
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To determine how augmentation enhances disease outcome, S. aureus population dynamics 117 
during infection were evaluated. We have previously identified a phagocyte-dependent 118 
immunological bottleneck, from which clonal expansion of a small number of bacteria results in 119 
characteristic kidney abscesses8. Mice were injected with three marked but otherwise isogenic, 120 
S. aureus strains in a 1:1:1 ratio totaling 1 x 106 CFU.  30 minutes post-infection, regardless of 121 
PGN addition, the majority of the CFU were in the liver and without PGN, bacterial numbers 122 
subsequently declined (Fig. 2i). As infection progressed there were significantly more S. aureus 123 
in the liver, kidneys and spleens of mice receiving mixed inocula. To understand clonal expansion 124 
in this context, we assessed contribution to the final bacterial load of the three marked strains, 125 
in each organ. By 70 hpi, dominance by individual or pairs of strains indicated clonal expansion 126 
in kidneys, but less so in the liver (Fig. 2j, Supplementary Data Fig. 2k,l). However, careful 127 
dissection and bacterial enumeration of individual liver abscesses showed these were clonal (Fig. 128 
2j, P<0.001).  129 
 130 
To determine the molecular basis for infection augmentation, PGNs from a range of species 131 
including Staphylococcus epidermidis, Curtobacterium flaccumfaciens, Bacillus subtilis and S. 132 
aureus strains were used. Infection could be augmented in the murine sepsis model by PGN from 133 
all species tested (Supplementary Data Fig. 3a-l), having a diversity of amino acids in the peptide 134 
side chain, suggesting the conserved glycan moiety is important. C. flaccumfaciens has unusual 135 
PGN for a Gram-positive organism as it contains glycine as the first peptide in the side chain as 136 
opposed to L-alanine. Bacillus subtilis PGN contains meso-diaminopimelic acid (m-DAP) at stem 137 
peptide position 3, an amino acid commonly found in the PGN of Gram-negative bacteria23. PGN 138 
from S. epidermidis however is similar to that of S. aureus, the only difference being altered 139 
composition of the crosslinking side chains. The presence of wall teichoic acids on PGN (i.e. the 140 
PGN was not HF treated) did not alter augmentation (Supplementary Data Fig. 3m-o). S. aureus 141 
lipoproteins are immunostimulatory via TLR224, however PGN from a lipoprotein deficient 142 
mutant (lipoprotein diacylglyceryl transferase, lgt) could still augment pathogenesis 143 
(Supplementary Data Fig. 3p ?r). Furthermore, solubilisation of PGN abrogates augmentation 144 
eliminating a contaminating moiety within the preparations as the mechanism of augmentation. 145 
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PGN can also augment infection in other murine models. Using S. aureus LS-1 and NMRI mice, M. 146 
luteus PGN caused increased severity in both septic arthritis (Fig. 2k, l) and subcutaneous abscess 147 
models (Supplementary Data Fig. 4a,b) in which PGN alone had no effect.   148 
 149 
Augmentation circumvents the immune bottleneck during pathogenesis which we have 150 
hypothesised occurs inside phagocytes8,9 (Fig. 2c). Therefore, we depleted either neutrophils or 151 
macrophages (and macrophage-like cells) prior to challenge in the murine sepsis model.  152 
Depletions led to an expected increased susceptibility to S. aureus, thus requiring a reduced 153 
inoculum of 1x105 CFU. Macrophage depletion using clodronate liposomes resulted in multiple, 154 
small liver abscesses reminiscent of PGN augmentation. However, addition of PGN to the 155 
inoculum did not lead to augmentation suggesting a critical role for macrophages (or related 156 
cells) in augmentation of pathogenesis (Fig. 3a). Conversely, infection of neutropenic mice was 157 
still PGN augmented (Fig. 3b) and this is in agreement with in vitro data where co-incubation of 158 
S. aureus and PGN with human derived neutrophils did not promote survival of S. aureus 159 
compared to bacteria only controls (Supplementary Data Fig. 4c). However, survival of 160 
intracellular S. aureus in human monocyte derived macrophages (MDMs) was increased in the 161 
presence of PGN (Supplementary Data Fig. 4d; P<0.01), demonstrating a potential human 162 
relevance for our findings. 163 
 164 
Augmentation of infection by PGN leads to liver abscesses, so to decipher organ and cellular level 165 
mechanisms, we employed spinning-disk intravital microscopy (SD-IVM) to visualise Kupffer cells 166 
(KC; liver-resident macrophages), and other innate immune cells. Polymorphonuclear 167 
neutrophils (PMNs) are crucial for S. aureus control by the host in both animal models25,26 and 168 
humans27. Additionally, an important role for KC in capturing and eliminating S. aureus during 169 
bacteremia has been recently described19,28. Fluorescently labelled PGN and S. aureus-GFP were 170 
co-injected into C57BL/6J mice and both were rapidly engulfed by KC (purple), but not 171 
neutrophils (red) (Fig. 3c, Video 1 and 2). The rate of S. aureus capture by KC was not perturbed 172 
by PGN augmentation (Fig. 3d). However, at 8 hpi mice receiving mixed inocula had significantly 173 
more S. aureus-GFP within the liver than controls and by 24 hpi they contained small, multi-lobar 174 
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focal abscesses (Fig. 3e), concomitant with an elevated S. aureus burden (Fig. 3f). Augmentation 175 
with PGN did not affect neutrophil recruitment at 8 hpi (Fig. 3g), but by 24 hpi there was a 176 
significant increase (Fig. 3g) consistent with abscess formation (Figs. 2f and 3e). These data 177 
suggest that a mixed inoculum leads to inadequate control of S. aureus inside KC. 178 
 179 
It has been previously shown that during natural colonisation of mice an immune tolerance to S. 180 
aureus infection occurs, mediated by Nod129.  To test whether prior exposure to commensal 181 
organisms affects augmentation, we tested the phenomenon in germ-free (GF) mice, which are 182 
incidentally more susceptible to S. aureus30.  Using SD-IVM it was observed that the rate of 183 
staphylococcal capture by KC is comparable to that seen in wildtype mice and importantly, S. 184 
aureus pathogenesis is augmented by particulate PGN (Supplementary Data Fig. 4e-g). 185 
 186 
Host PGN recognition has been attributed to TLR2 receptors, however this is now known to be 187 
due to lipoprotein contamination31. We demonstrated no role for MyD88 dependent signaling in 188 
augmentation and also ruled out the cytosolic PGN receptor Nod2 and the NLRP3 inflammasome 189 
(Fig. 4a,b). Furthermore, the range of PGN structures able to augment precluded a role for Nod132 190 
and the NLRP3 inflammasome33 (Supplementary Data Fig. 3a-l). However, Cybb-/- mice, missing 191 
the NADPH oxidase34, required by phagocytes to produce reactive oxygen species (ROS), showed 192 
lack of augmentation at 8 hpi (Fig. 4b). Cybb-/- mice are highly susceptible to S. aureus infection 193 
(Fig. 4b), not surviving until 24 hpi. At a lower inoculum of 105 CFU, 8 hpi imaging was not possible 194 
due to low fluorescence levels, but at 24 hpi, augmentation was still not observed (Fig. 4c) 195 
confirming the likely mechanistic involvement of ROS. Augmentation with PGN led to greatly 196 
diminished oxidation (P<0.0001) and to less acidification (P<0.01) of the phagolysosomes 197 
containing S. aureus in KC (Fig. 4d-f, Video 3 and 4), highlighting the critical role of ROS. 198 
 199 
A characteristic feature of many S. aureus infection models is a high inoculum. Here we have 200 
established that the majority of the infecting material can be commensal bacteria or even cell 201 
wall peptidoglycan. This has important implications for infection prevention where both the 202 
pathogen and other organisms or material, previously thought innocuous, need to be considered. 203 
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Deciphering the cellular and molecular mechanisms involved will allow exploitation for 204 
development of novel interventions17,35,36. Potentially S. aureus responds to augmenting material 205 
resulting in an increased capability of the pathogen to initiate infection.  P. aeruginosa is known 206 
to respond to PGN to enhance its virulence37. As well as at the initiation of infection, 207 
augmentation could occur during the action of antibiotics, where death of a proportion of the 208 
bacterial population may give rise to cell wall fragments.  Also, indwelling medical devices, such 209 
as intravascular catheters, reside in-situ for several days where the prosthetic material can 210 
become colonised by commensal flora15. As catheters are regularly accessed, both commensal 211 
flora (e.g. M. luteus and S. epidermidis) and pathogen (S. aureus) could be flushed into the 212 
bloodstream simultaneously. Our work establishes a precedent for how a human pathogen can 213 
initiate disease using proinfectious agents, as microbial crowdsourcing to circumvent immune 214 
system control. In clinical practice, infection by all bacterial pathogens occurs from within a 215 
microflora and is therefore initially polymicrobial. This raises the likelihood of a more general role 216 
for proinfectious agents, requiring revision of existing models of bacterial pathogenesis and 217 
highlighting the involvement of commensal organisms as unwitting accomplices in infection 218 
initiation. 219 
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Figure 1 S. aureus virulence is augmented by live commensal flora  250 
a, Survival curves of fish injected with low dose S. aureus SH1000 (150 CFU, SA low) and/or S. 251 
aureus SH1000 phePsaeR (1350 CFU). S. aureus SH1000 high dose (1500 CFU, SA high) was 252 
injected as a positive control. Data are representative of three independent experiments; n t 28, 253 
log-rank (Mantel-Cox) test. b, Survival of fish injected with low dose S. aureus SH1000 (150 CFU, 254 
SA low) with or without live or heat killed (HK) M. luteus (2000 CFU, ML). Data are representative 255 
of three independent experiments; n t 28, log-rank (Mantel-Cox) test. c, Growth of bacteria 256 
within embryos after co-injection with M. luteus (2000 CFU) and S. aureus SH1000 (150 CFU). 257 
Open circles, live and filled circles, dead embryos, M. luteus (red), S. aureus (black) CFU in each 258 
fish. n t 60. d, In vivo imaging of pHrodo (red) labelled M. luteus (2000 CFU, ML indicated by 259 
arrows) and S. aureus SH1000-GFP (150 CFU, SA indicated by arrows) 2 hpi. Within the zebrafish 260 
circulation valley, phagocytes were viewed at x 60 magnification). Images are representative of 261 
5 embryos from ƚǁŽŝŶĚĞƉĞŶĚĞŶƚĞǆƉĞƌŝŵĞŶƚƐ ?^ĐĂůĞďĂƌ ? ?ʅŵ ?e,f, Co-injection of live 1x108 262 
CFU S. epidermidis (SE) and low dose (1x106 CFU) S. aureus NEWHG into mice (SA) with weight 263 
loss (e) and liver CFU (f) recorded (S. aureus, black; S. epidermidis, red). n = 10 per group; median 264 
value shown, Mann-Whitney two-sided test. g,h, Co-injection of live M. luteus (ML, 2x108 CFU) 265 
and low dose S. aureus NEWHG (SA, 1x106 CFU) into mice with weight loss (g) and liver CFU (S. 266 
aureus) (h) recorded. n = 10-20 per group; median value shown, Mann-Whitney two-sided test. 267 
i, Dermonecrotic lesion size for C57BL/6J mice injected (on the left flank) with S. aureus NewHG 268 
(SA, 107 CFU, n= 13) or co-injected with S. aureus NewHG 107 CFU and either isolated skin 269 
commensals from SPF mice (SA  & SPF harvest, n= 8) or skin commensals from GF mice (SA & GF 270 
harvest, n=5). Median value shown, one-way ANOVA with Tukey post-test.  271 
  272 
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Figure 2 Gram-positive PGN augments S. aureus pathogenesis in animal models 273 
a, Survival curves of fish injected with low dose S. aureus SH1000 (150 CFU, SA low) and 5 ng 274 
polymeric M. luteus PGN (ML pPGN). S. aureus SH1000 high dose (1500 CFU, SA high) was injected 275 
as a positive control. Data are representative of three independent experiments; n t 28, log-rank 276 
(Mantel-Cox) test. b, Growth of bacteria within embryos after co-injection with low dose S. 277 
aureus SH1000 (150 CFU) and 5 ng M. luteus PGN. Open circles, live and filled circles, dead 278 
embryos. n t 60. c, In vivo imaging of Alexafluor 647 (blue) labelled M. luteus PGN (5 ng, ML PGN 279 
indicated by arrow) and S. aureus SH1000-GFP (150 CFU, SA indicated by arrow) 2 hpi. Within the 280 
zebrafish circulation valley, phagocytes were viewed at x 60 magnification). Images are 281 
representative of 5 embryos from two independent experiments. Scale ďĂƌ ? ?ʅŵ ?d, e, BALB/c 282 
mice were injected i.v. with low dose (1x106 CFU) S. aureus NEWHGkan with or without 500 ʅŐ M. 283 
luteus particulate PGN (pPGN) or soluble PGN (sPGN). Weight loss (d) and liver (e) CFU were 284 
measured. n = 10 per group; median value shown, Mann-Whitney two-sided test. f, 285 
Representative images of histopathological changes during infection. Arrows show 1, large 286 
abscess within liver parenchyma;͒2, accumulation of extracellular S. aureus; 3, dense infiltrate of 287 
polymorphonuclear leukocytes (PMNs). Inset box at x10 magnification (scale bar 100 Pm) is 288 
displayed at x100 (scale bar 10 Pm) in bottom panels. n = 5 per group. g, Liver CFU recovered 289 
from BALB/c mice injected i.v. with a decreasing dose of S. aureus NEWHGkan with or without 500 290 
ʅŐ M. luteus pPGN. n = 5 per group; median value shown, Mann-Whitney two-sided test. h, Liver 291 
CFU recovered from BALB/c mice injected i.v. with low dose (1x106 CFU) S. aureus NEWHGkan with 292 
or without a decreasing dose of M. luteus pPGN. n = 5 per group; median value shown, Mann-293 
Whitney two-sided test. i, Liver CFU at various time points after co-injection of low dose (1x106 294 
CFU) S. aureus with or without 500 ʅŐ M. luteus pPGN. n = 8 per group; median value shown, 295 
Mann-Whitney two-sided test. j, Livers from mice injected with low dose (1x106 CFU; 1:1:1 296 
mixture of NewHG EryR, TetR or KanR, n = 5 per group S. aureus NEWHGkan ƉůƵƐ ? ? ?ʅŐM. luteus 297 
PGN were harvested. Individual abscesses were dissected and bacterial CFU enumeration from 298 
each abscess was determined (A1-A4). Bacterial CFUs from residual liver tissue post dissection (-299 
) was also enumerated and added to the abscess CFUs to provide a total CFU count for each liver 300 
(L). k, Micro-CT imaging of knee and front right paw of an NMRI mouse injected i.v. with low dose 301 
(1x106 CFU) S. aureus LS-1 with or without 1 mg M. luteus pPGN. Images are representative of 10 302 
animals. l, Clinical arthritis severity of NMRI mice injected i.v. with S. aureus LS-1 low dose (1x106 303 
CFU) and 1 mg M. luteus pPGN. dpi, days post infection. n = 10 per group; error bars, mean and 304 
s.e.m, Mann-Whitney two-sided test. * P < 0.05.  305 
 306 
 307 
 308 
  309 
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Figure 3 Kupffer cells are key mediators of augmentation 310 
a, Liver CFUs of BALB/c mice injected i.v. with low dose (1x105 CFU) S. aureus NEWHG with or 311 
without 500 ʅŐM. luteus PGN post treatment with empty liposomes or clodronate. n = 10 per 312 
group; median value shown, Mann-Whitney two-sided test. b, Liver CFUs of BALB/c mice injected 313 
i.v. with low dose (5x105 CFU) S. aureus NEWHG with or without 500 ʅŐM. luteus PGN post 314 
treatment with anti-Ly6G. n = 9-10 per group; median value shown, Mann-Whitney two-sided 315 
test. c, Representative SD-IVM images of liver neutrophils (Ly6g; red) and Kupffer cells (KC) 316 
(F4/80; purple) at baseline or after i.v. injection of S. aureus (5x107 CFU, BSG1; green) or S. aureus 317 
plus S. epidermidis PGN (PGN-AF647; blue) at 15 min in female C57BL/6J ŵŝĐĞ ?ƐĐĂůĞďĂƌƐ ? ?ʅŵ ?318 
Insert shows higher magnification image of KCs with internalized S. epidermidis PGN and S. 319 
aureus ?^ĐĂůĞďĂƌ ? ?ʅŵ ?n = 5 per group. d, Quantification of SD-IVM images of S. aureus (5x107 320 
CFU, BSG1) catching by KC in the livers of female C57BL/6J mice with (red) and without (black) 321 
co-injection of 500 µg S. epidermidis PGN (FOV  ? field of view); n = 4; thin lines, mean and s.e.m. 322 
e, Representative stitched SD-IVM images of mouse livers at 8 h (infected with S. aureus, 107 CFU, 323 
BSG1) or 24 h (infected with S. aureus 106 CFU, BSG1) with and without co-injection of 500 µg S. 324 
epidermidis PGN in male C57BL/6J; scale bar 250 µm; n = 5. f, Quantification of 2 mm2 stitched 325 
SD-IVM images for GFP-fluorescence (S. aureus, BSG1) in murine livers, assessed at 24 h post i.v. 326 
injection of S. aureus with or without S. epidermidis PGN. n = 5 per group; mean value shown, 327 
Mann-Whitney two-sided test. g, Quantification of 2mm2 stitched SD-IVM images for TdTomato 328 
fluorescence (Neutrophils) assessed at 8 h post i.v. injection with S. aureus (107 CFU, BSG1) or at 329 
24 h post i.v. injection with S. aureus (106 CFU, BSG1) with and without co-injection of S 330 
epidermidis PGN in Catchup mice. n = 4-5 per group. Error bars, mean with Ɛ ?Ğ ?ŵ ?dƵŬĞǇ ?ƐŵƵůƚŝƉůĞ331 
comparisons test applied. 332 
 333 
  334 
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Figure 4 Reduced oxidative burst in KCs permits augmentation of S. aureus virulence 335 
 a,b, Representative SD-IVM image of mouse livers (a) or quantification of 2 mm2 stitched SD-336 
IVM images for GFP-fluorescence, ƐĐĂůĞďĂƌ  ? ?ʅŵ (b) at 8 h after i.v. infection with S. aureus 337 
BSG1 (SA, 107 CFU) with and without co-injection of 500 µg PGN in male C57BL/6J, Nod2-/-, 338 
MyD88-/-, NLRP3-/- or Cybb-/- mice, n = 4 per group; mean shown, error bar s.d, unpaired t-test 339 
two-tailed. c, Quantification of 2 mm2 stitched SD-IVM images for GFP-fluorescence at 24 h after 340 
i.v. infection with S. aureus BSG1 (SA, 105 CFU) with and without co-injection of 500 µg PGN in 341 
male C57BL/6J or Cybb-/- mice, n = 4 per group; error bar s.d. d, SD-IVM image of mouse livers 342 
injected with pH-rodo S. aureus bioparticles (red) additionally labelled with AF647 (blue) as a 343 
reference fluorophore and OxyBURST (green) with and without (control) co-injection of 500 µg 344 
W'EĂƚ ?ĂŶĚ ? ?ŵŝŶƉŽƐƚŝŶĨĞĐƚŝŽŶ ?ƐĐĂůĞďĂƌ ? ?ʅŵ ?Arrows point to oxidized bioparticles. n = 3 345 
per group. e,f, Quantification of intracellular acidification of pH-rodo (e) or oxidation of 346 
OxyBURST labelled S. aureus bioparticles (f) in KC over time in C57BL/6J mice with and without 347 
(control) co-injection of 500 µg PGN. Data represent the mean fluorescence of S. aureus 348 
bioparticles compiled from five separate FOV per time point, n = 3 per group, error bars, s.e.m, 349 
two-way ANOVA.  350 
  351 
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 352 
Species Strain Description Reference 
Staphylococcus 
aureus 
SH1000 rsbU+ derivative of S. aureus 8325-4 38 
Staphylococcus 
aureus 
NewHG Newman with saeSL allele from strain RN1 39 
Staphylococcus 
aureus 
Newman NCTC 8178  40 
Staphylococcus 
aureus 
BSG 1 NewHG carrying pCM29-GFP 41,42 
Staphylococcus 
aureus 
BSG 2 MW2 carrying pCM29-GFP 42 
Staphylococcus 
aureus 
JE2 USA300 LAC cured of p01 and p03 43 
Staphylococcus 
aureus 
NewHGery NewHG lysA::pGM068 (EryR) lysA+ 8 
Staphylococcus 
aureus 
NewHGkan NewHG lysA::pGM072 (KanR) lysA+ 8 
Staphylococcus 
aureus 
NewHGtet NewHG lysA::pGM070 (TetR) lysA+ 8 
Staphylococcus 
aureus 
TJ1 LS1 44 
Staphylococcus 
aureus 
SH1000 GFP SH1000 carrying pMV158-GFP This study 
Staphylococcus 
aureus 
SH1000 
mCherry 
SH1000 carrying pMV158-mCherry This study 
Staphylococcus 
aureus 
phePsaeR SH1000 sae::EryR pheP::TetR This study 
Staphylococcus 
aureus 
SA113 lgt::ermB 31 
Staphylococcus 
aureus 
SJF4591 SH1000lgt::ermB  This study 
Micrococcus luteus SJF 256 ATCC 4698 Sigma 
Micrococcus luteus SJF4393 ATCC 4698 (RifR) This study 
Staphylococcus 
epidermidis 
SJF229 138  45 
Staphylococcus 
epidermidis 
SJF4381 138 (RifR) This study 
Bacillus subtilis SJF 1 168 Lab stock 
Bacillus cereus SJF 1657 ATCC 14579 Lab stock 
Curtobacterium 
flaccumfaciens 
SJF 449  Wildtype Lab stock 
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Table 1: Bacterial species and strains and plasmids used in this study  353 
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Strain Description Source 
BALB/c Wildtype Charles River Laboratories 
C57BL/6J Wildtype The Jackson Laboratory 
Cybb-/- Cybb-deficient The Jackson Laboratory 
MyD88-/- MyD88 deficient The Jackson Laboratory 
Nod2-/- Nod2 deficient The Jackson Laboratory 
NLRP3-/- NLRP3 deficient The Jackson Laboratory 
Catchup TdTomato driven from Ly6G-cre University of Duisbury-Essen46 
NMRI Wildtype Charles River Laboratories 
SPF Wildtype C57BL/6J Taconic or the Jackson Laboratory 
Germ-free 
C57BL/6J 
Germ-free wildtype C57BL/6J 
Taconic, or The Jackson 
Laboratory and rederived under 
Germ-free conditions47 
Table 2. Mouse strains used in this study 354 
 355 
 356 
 357 
 358 
 359 
 360 
  361 
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Methods 362 
Bacterial strains and culture conditions 363 
S. aureus, M. luteus, C. flaccumfaciens and S. epidermidis strains (Table 1) were grown using brain 364 
heart infusion (BHI) liquid or solid medium (Oxoid) at 37°C with the exception of M. luteus which 365 
was grown at 30°C. Bacillus sp. strains were grown using nutrient agar liquid or solid medium 366 
(Oxoid) at 37°C. Supplementation with the following antibiotics was added where appropriate: 367 
kanamycin 50 µg/ml, tetracycline 5 µg/ml or erythromycin 5 µg/ml plus lincomycin 25 µg/ml 368 
(Sigma-Aldrich). To distinguish bacterial populations in mixed inocula experiments, M. luteus was 369 
ƐĞƌŝĂůůǇƉĂƐƐĂŐĞĚŽŶ,/ŵĞĚŝĂǁŝƚŚŽƌǁŝƚŚŽƵƚƌŝĨĂŵƉŝĐŝŶ ? ? ? ? ?ʅŐŵů-1) and incubated at 30°C 370 
until a rifampicin resistant derivative was identified. The same was conducted for S. epidermidis. 371 
For all murine experiments, pre-grown batches of bacteria were thawed, washed and diluted to 372 
the desired concentration in endotoxin-free PBS (Sigma). Staining of bacterial cells for microscopy 373 
was carried out as described for PGN below. SH1000 mCherry and SH1000 GFP were constructed 374 
as follows. The pMV158mCherry plasmid was constructed by introducing a gene encoding 375 
mCherry (Uniprot: X5DSL3-1) into pMV158GFP48 and replacing the existing GFP gene. The 376 
plasmids, pMV158GFP and pMV158mCherry, were then introduced into S. aureus RN4220 by 377 
electroporation, resulting in transformants expressing GFP and mCherry, respectively. The 378 
plasmids were subsequently transferred into S. aureus ^, ? ? ? ? ďǇ Ɍ ? ? ƚƌĂŶƐĚƵĐƚŝŽŶ ĂŶĚ ƚŚĞ379 
obtained transductants were verified by fluorescence microscopy. To create an avirulent S. 380 
aureus mutant, SH1000pheP11 (deficient in amino acid permease) was transduced into 381 
SH1000saeR49 (mutation affecting the two component system required for innate immune 382 
evasion) ƵƐŝŶŐ ʔ  ? ? ƉŚĂŐĞ ? dŚĞ ƐĂŵĞ ƉŚĂŐĞ ǁĂƐ ƵƐĞĚ ƚŽ ƚƌĂŶƐĚƵĐĞ lgt::ermB from S. aureus 383 
SA113 background into SH1000.  384 
 385 
Preparation of latex beads, peptidoglycan and bioparticles 386 
For in vivo ůĂƚĞǆ ďĞĂĚ ĞǆƉĞƌŝŵĞŶƚƐ ? ƉŽůǇƐƚǇƌĞŶĞ ůĂƚĞǆ ďĞĂĚƐ  ? ? ? ?ʅŵ ? ^ŝŐŵĂ ? ǁĞƌĞ ǁĂƐŚĞĚ ŝŶ387 
endotoxin free PBS, diluted to the desired concentrations and sonicated for 3 x 30 sec (Soniprep 388 
150, MSE, UK) prior to injection into infection models. To prepare PGN, a mid-exponential phase 389 
bacterial culture was prepared in appropriate medium and purification was carried out as 390 
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previously described50. Endotoxin assay was carried out using Pyrochrome (Associates of Cape 391 
ŽĚ/ŶĐ ? ?ĂƐƉĞƌŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?No significant difference in endotoxin concentration 392 
was detected between enzyme only control and the various solubilised Gram-positive PGN 393 
preparations. To solubilŝƐĞW'E ? ? ? ?ʅŐŵů-1 mutanolysin (50 mM sodium phosphate buffer, pH 394 
5.5) was added and incubated at 37°C overnight on a rotary shaker (100 rpm). Thereafter, the 395 
mixture was heated to 95°C for 5 mins before being centrifuged (13 000 rpm, 8 min) to remove 396 
any remaining insoluble material. Succinimidyl esters (Life Technologies) were used to stain PGN. 397 
pHrodo (2.5 mM), Fluorescein-5- EX (16.95 mM) or Alexa-Fluor 647 were used as per 398 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐƉƌŽƚŽĐŽůƐ ? /ŶďƌŝĞĨ ?  ?ŵŐW'EǁĂƐƌĞĐŽǀĞƌĞĚďǇĐĞŶƚƌŝĨƵŐĂƚŝŽŶ  ?13 000 rpm, 2 399 
ŵŝŶ ?ĂŶĚƌĞƐƵƐƉĞŶĚĞĚŝŶĂŶĂƉƉƌŽƉƌŝĂƚĞǀŽůƵŵĞŽĨW^Ɖ, ?ĂŶĚ ? ? ?ʅůŽĨƚŚĞƐƵƐƉĞŶƐŝŽŶŵŝǆĞĚ400 
ŝŶĂŵŝĐƌŽĐĞŶƚƌŝĨƵŐĞƚƵďĞǁŝƚŚ ?ʅůŽĨ -^ester. After 30 min incubation at 37°C on a rotary shaker 401 
(100 rpm), excess dye was removed by sequential washing in PBS pH 8, Tris pH 8.5 and again in 402 
PBS pH 8 each followed by mixing, centrifugation and gentle removal of the supernatant. Stained 403 
PGN was finally re-ƐƵƐƉĞŶĚĞĚ ŝŶ  ? ? ? ʅů W^ Ɖ,  ? ? ? ? ^ƚĂƉŚǇůŽĐŽĐĐĂů Ɖ,ƌŽĚŽ ďŝŽƉĂƌƚŝĐůĞƐ  ?>ŝĨĞ404 
Technologies) were additionally labelled with Alexa-Fluor 647 Succinimidyl ester (Life 405 
dĞĐŚŶŽůŽŐŝĞƐ ? ĂŶĚ KǆǇhZ^d ŐƌĞĞŶ  ?, ?& ^ ? ĂĐĐŽƌĚŝŶŐ ƚŽ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ƉƌŽƚŽĐŽůƐ ƚŽ406 
generate reporter bioparticles for acidification and oxidation. pHrodo red S. aureus BioParticles 407 
were labeled at 2 mg mlAL1 with 50 µg mlAL1 AlexaFluor 647 NHS ester and 100 µg mlAL1 OxyBURST 408 
in 100 mM bicarbonate, pH 8.3, buffered saline for 30 min at room temperature under vigorous 409 
agitation. Activation of OxyBURST was accomplished by adding 250 µl 1.5 M hydroxylamine, pH 410 
8.5, and incubating for 30 min on ice. Labelled BioParticles were washed twice with PBS and 411 
checked for labeling efficiency by flow cytometry or injected i.v. into mice. 412 
 413 
 414 
Phagocyte bacterial challenge and quantification of viable intracellular bacteria  415 
Human blood was obtained from healthy volunteers, with informed consent, in compliance with 416 
the guidelines of the South Sheffield Research Ethics Committee (07/Q2305/7).  417 
 418 
Neutrophils were purified from anti-coagulated human blood as previously described51. In 419 
triplicate and with two biological repeats, approximately 2.5x106 cells/ml were co-incubated at 420 
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37°C with S. aureus NewHG bacteria to produce a multiplicity of infection (MOI) of 5 in the 421 
presence or absence of M. luteus PGN. At 30 and 90 min post co-culture, extracellular and 422 
intracellular CFU was calculated. To measure intracellular CFU, the co-culture was transferred to 423 
a microcentrifuge tube, centrifuged at 2000 rpm for 2 mins before the supernatant was removed. 424 
The neutrophils were then lysed with 1% (w/v) saponin for 10 mins at RT. Bacterial enumeration 425 
was calculated from serial dilutions. At 90 mins, lysostaphin (20 Pg ml-1) was added to the 426 
remaining co-culture wells for 30 mins to lyse extracellular bacteria for the final 120 minute 427 
timepoint. 428 
 429 
Monocyte derived macrophages (MDMs) were isolated from peripheral blood mononuclear cells 430 
(PBMCs) from healthy donors, as previously described52. PBMCs were isolated by Ficoll Plaque 431 
(GE Healthcare) density centrifugation, seeded at 2x106 cells/ml in RPMI 1640 medium with 2 432 
mmol/l L-glutamine (Lonza) supplemented with 10% v/v newborn foetal calf serum (Gibco) in 24 433 
well plates (Corning) with 1 ml/well to achieve approximately 2x105 MDM/ml. After 24 hours, 434 
non-adherent cells were removed and adherent cells were cultured in RPMI 1640 medium with 435 
2 mmol/l L-glutamine supplemented with 10% v/v low endotoxin heat inactivated foetal calf 436 
serum (Biosera) and used at 14 days. Differentiated MDMs were challenged with S. aureus 437 
NewHG at a MOI of 0.5. The bacteria were thawed, washed in PBS and added to the MDMs in 438 
fresh media. M. luteus PGN (sonicated for 3 x 30 s bursts) was added to the bacteria-containing 439 
media at a concentration of 100 Pg/ml. The MDMs were incubated on ice for 1 hour then at 37qC, 440 
5% v/v CO2. Following a 4-h total challenge, infected media was removed and the MDMs washed 441 
with ice cold PBS. Residual extracellular bacteria were killed by addition of 100 Pg/ml gentamicin 442 
in fresh media and incubated for 30 mins, then maintained in media containing 20 Pg/ml of 443 
gentamicin (Sanofi-Aventis) until the desired time point. MDMs were washed with PBS and 444 
incubated with 2% v/v saponin (Sigma) at 37qC for 12 min. PBS was added and cells lysed by 445 
scraping and pipetting. Estimation of viable intracellular bacteria was determined by surface 446 
viable count6. To confirm complete killing of extracellular bacteria, some wells were fixed with 447 
2% v/v paraformaldehyde before bacterial challenge, then exposed to gentamicin and lysed as 448 
described, demonstrating absence of bacteria in lysates. Intracellular killing after initial bacterial 449 
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challenge was estimated by lysing cells maintained in 20 Pg/ml of gentamicin for 0.5h  ? 3.5h. 450 
 451 
Animal experiments 452 
Murine work was carried out according to UK law in the Animals (Scientific Procedures) Act 1986, 453 
under Project License PPL 40/3699; approved by the Animal Research Ethical Committee of 454 
Gothenburg or approved by the University of Calgary Animal Care Committee (AC12 0162) in 455 
compliance with the Canadian Council for Animal Care Guidelines.   456 
 457 
Murine models 458 
All mice (Table 2) were housed in designated animal facilities in standard environmental 459 
conditions of temperature and light and fed laboratory chow and water ad libitum. For the 460 
haematogenous septic arthritis model, S. aureus LS-144 was inoculated i.v. into the tail vein 461 
female of NMRI mice (n=10), 6-8 weeks old (Charles River Laboratories, Germany) with 0.2 ml of 462 
low dose LS-1 (1x106 CFU), with or without 1 mg M. luteus PGN. Mice were regularly weighed 463 
and examined for clinical arthritis by observers blinded to the groups as previously described53. 464 
In brief, a clinical scoring system ranging from 0 ?3 was used for each paw (0- no inflammation; 465 
1- mild visible swelling and/or erythema; 2- moderate swelling and/or erythema; 3- marked 466 
swelling and/or erythema). The clinical arthritis severity overall score was constructed by adding 467 
the scores from all 4 limbs for each animal. On day 10, mice were sacrificed and limbs were 468 
resected for microcomputed tomography (micro-CT) radiological examination of bone erosion.  469 
 470 
For the staphylococcal skin infection model, NMRI mice (n=18) were anaesthetised with 471 
ketamine/medetomidine and the dorsum was shaved before subcutaneous (s.c.) injection of one 472 
flank with 0.05 ml of S. aureus SH1000 (1x106 CFU/spot) and a mixture of SH1000 (1x106 473 
CFU/spot) with PGN (250 µg/spot) in the other flank. PGN alone did not cause any inflammation 474 
or skin lesions. Two observers blinded to the treatment groups measured the lesion size of each 475 
mouse with a caliper on day 4. The skin lesion was calculated using the mathematical formula for 476 
the area of an ellipse. After sacrificing the mice on day 4, skin was disinfected with 70% v/v 477 
ethanol and skin biopsies encompassing the entire infected area were taken with a sterile 8 mm 478 
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biopsy puncher (Kai Medical, Seki, Japan). Biopsy samples were homogenised (Ultra Turrax T25 479 
homogeniser, Germany) and viable counts of bacteria were assessed54.  480 
 481 
For the mouse sepsis model, female BALB/c mice (Charles River Laboratories, UK) or male and 482 
female C57BL/6 at 7-8 weeks old (The Jackson Laboratory) were inoculated in the tail vein with 483 
0.1 ml S. aureus (NEWHG or JE2), M. luteus or S. epidermidis either alone (dose range 102  ? 107 484 
CFU as indicated) or with PGN (50 µg - 1 mg as indicated) or with PGN only. Mice were monitored 485 
and sacrificed at 72 hpi unless otherwise stated or according to experimental design. Mouse 486 
organs were individually homogenised in PBS and after serial dilution, plated onto BHI agar 487 
supplemented with antibiotics as needed for bacterial number enumeration. Germ-free (GF) and 488 
C57BL/6(J) mice were bred and maintained in flexible-film isolators or in individually ventilated 489 
cages (IVC) at the Clean Mouse Facility, University of Bern, Switzerland. At the age of 6 weeks 490 
these mice were shipped under germ-free conditions to the University of Calgary. Alternatively, 491 
GF mice were obtained from Taconic.  GF status was routinely monitored by culture-dependent 492 
and -independent methods and all mice were independently confirmed to be pathogen-free. 493 
 494 
For the dermonecrosis model, mice were left in their cage without changing the bedding material 495 
for at least 7 days. Mice were euthanized and skin samples (2cm2) were surgically removed from 496 
the abdominal region of specific pathogen free (SPF) C57BL/6J or GF mice. Isolation of skin 497 
microorganisms was performed by incubation of the skin samples in PBS containing 0.1% Triton 498 
X-100 for 1hr at 37°C at high agitation. Skins were gently massaged against a 100 µm filter with 499 
additional PBS-Triton. Isolated microorganisms were centrifuged and washed 3x with PBS and 500 
stored on ice until the infection experiment. Skin microbes were enumerated by culturing on TSA 501 
blood agar plates for 48 hours at 25°C. 24 hours prior to infection experiments hair from the 502 
dorsal region of C57BL/6J mice was removed by shaving and hair removal cream (Nair). The left 503 
dorsal flank of each mouse was subcutaneously injected with 107 CFU S. aureus (injection volume 504 
50 µL) and the right dorsal flank received a co-injection of the isolated skin microbes and 107 CFU 505 
S. aureus. At 48 hpi mice were euthanized and skin lesions were photographed. Dermonecrotic 506 
lesion area was measured using ImageJ.  507 
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For SD-IVM experiments, a tail vein catheter was inserted into mice after anesthetization with 508 
200 mg kgAL1 ketamine (Bayer Animal Health) and 10 mg kgAL1 xylazine (Bimeda-MTC). Surgical 509 
preparation of the liver for intravital imaging was performed as previously described55. Mouse 510 
body temperature was maintained at 37°C with a heated stage. Image acquisition was performed 511 
using an Olympus IX81 inverted microscope, equipped with an Olympus focus drive and a 512 
motorized stage (Applied Scientific Instrumentation) and fitted with a motorized objective turret 513 
equipped with 4×/0.16 UPLANSAPO, 10×/0.40 UPLANSAPO, and 20×/0.70 UPLANSAPO objective 514 
lenses and coupled to a confocal light path (WaveFx; Quorum Technologies) based on a modified 515 
Yokogawa CSU-10 head (Yokogawa Electric Corporation). Target cells were visualized using 516 
fluorescently stained antibodies or fluorescent reporter bacteria. Typically, KCs and neutrophils 517 
were stained by i.v. injection of 2.5 µg anti ?F4-80 or 3.5 µg anti-ly6G fluorescent conjugated 518 
mAbs. Laser excitation wavelengths 491, 561, 642, and 730 nm (Cobolt) were used in rapid 519 
succession, together with the appropriate band-pass filters (Semrock). A back-thinned EMCCD 520 
512 × 512 pixel camera was used for fluorescence detection (Hamamatsu). Volocity software 521 
(Perkin Elmer) was used to drive the confocal microscope and for 3D rendering, acquisition, and 522 
analysis of images. For quantification of staphylococcal catching or measurements of Bioparticle 523 
oxidation and acidification in the liver, five random fields of view (FOV) with 10× objective were 524 
selected before injection of bacteria. Fluorescent reporter bacteria or reporter Bioparticles were 525 
injected i.v. into mice 1 min after initiation of acquiring background images. Find objects function 526 
in Volocity software was used to identify individual captured bacteria or Bioparticles by Kupffer 527 
cells (F4/80+ cells in liver) and when appropriate autofluorescent spots were subtracted from the 528 
final quantification. For Bioparticles the particles were selected in the AF647 reference channel 529 
and an increase in pHrodo (acidification) and OxyBURST (oxidation) fluorescence was quantified 530 
in the first hour after infection. Quantification of SD-IVM images; 4 hpi, computer generated 531 
stitched images of 2mm2 were generated using the stitched image function in Volocity. Volocity 532 
software was also used to quantify relative GFP fluorescence as a measurement of the presence 533 
of S. aureus-GFP or TD-tomato for the quantification of neutrophils in the liver after 534 
staphylococcal infection. SD-IVM images of uninfected mice were used to determine the 535 
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background fluorescence and S. aureus-GFP was quantified with the same settings for all mutants 536 
and treatments.  537 
 538 
Macrophage and Neutrophil depletion 539 
Macrophages were depleted using clodronate liposomes (NvR). The mice were injected i.v. with 540 
 ?ŵůŽĨůŝƉŽƐŽŵĞƐƉĞƌ ? ? ?ŐŽŶĚĂǇ ?ĂƐƉĞƌŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ?dŚĞŵŝĐĞǁĞƌĞƚŚĞŶ541 
injected with 1x105 CFU of S. aureus NewHG (1:1:1 mixture of NewHG EryR, TetR or KanR) on day 542 
2. Blank liposomes were used as a control. Macrophage depletion was confirmed using histology 543 
sections of the liver stained with anti-macrophage antibody (rat anti mouse F4/80, AbD Serotec, 544 
catalog number MCA497R). For antibody based neutrophil depletion, in vivo anti-ly6G mouse 545 
antibody (1A8, BioXcell, catalog number BE0075-1) was used as per the previously published 546 
protocol56. The mice were injected with 1.5 mg/mouse of antibody (200 µl per mouse) on day 1 547 
with the mice being injected with 5x105 CFU S. aureus NewHG (1:1:1 mixture of NewHG EryR, TetR 548 
or KanR) on day 2. 100 µl of blood was collected via tail bleeding at the time of S. aureus injection 549 
and at the end of the experiment via terminal anaesthesia and heart puncture. The blood samples 550 
were mixed with 20 µl of Heparin each and then stained with APC Rat Anti-Mouse Ly-6G antibody 551 
(BD biosciences, catalog number 560599) according to the BD bioscience protocol. The samples 552 
were then processed using the BD LSRII flow cytometer to confirm neutrophil depletion. 553 
 554 
Histological analysis of mouse organs 555 
Carried out within a liquid nitrogen dewar, individual organs were placed in an embedding cube, 556 
partially pre-filled with optimal cutting temperature (OCT) medium. Ensuring correct positioning 557 
for optimal sectioning, the remaining cube was filled with medium and stored at -80°C. Pre-558 
sectioning, organs were placed at - ? ? ? ĂŶĚ  ? ? ? ʅŵ ƐůŝĐĞƐ ǁĞƌĞ ƚĂŬĞŶ ďĞĨŽƌĞ ƐƚĂŝŶŝŶŐ ǁŝƚŚ559 
hematoxylin and eosin (H&E) stain as previously established49.  560 
 561 
Zebrafish model 562 
Zebrafish embryos less than 5 days post fertilisation (dpf) are not protected under the Animals 563 
(Scientific Procedures) Act 1986 but all zebrafish work was carried out according to the details 564 
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set out in Project License PPL 40/3574.  565 
 566 
For zebrafish experiments, London wild-type (LWT) embryos were incubated in E3 medium at 567 
28°C according to standard protocols57. Embryos were microinjected at 30 hours post fertilization 568 
(hpf) into the circulation valley as previously described10. Following injection, embryos were kept 569 
individually in 100 µl E3 medium and survival recorded for up to 90 hpi. For bacterial growth 570 
experiments in vivo, at various time points, embryos were collected and bacterial numbers 571 
enumerated as described for mouse organs above.  572 
   573 
For microscopy, live anaesthetised zebrafish were mounted onto 15 mm petri dishes in 1% (w/v) 574 
low melting point agarose and E3 solution. Images were acquired using either the TE-2000U 575 
microscope (Nikon) with a Hamamatsu Orca-AG camera (objectives used: 4× Nikon Plan Fluor 576 
objective NA 0.13 and 60× Nikon Plan Apo oil objective NA 1.4; fluorophores excited with either 577 
488 nm (GFP) or 543 nm (mCherry)) or the UltraVIEW VoX spinning disk confocal microscope 578 
(Perkin Elmer) (GFP, mCherry and Alexa Fluor® 647 were excited by the 457-51 nm argon laser, 579 
561 nm sapphire laser and 642 nm diode laser, respectively). Image acquisition and processing 580 
were performed with Volocity software. 581 
 582 
Statistical analysis 583 
Sample sizes were predetermined for mouse and zebrafish experiments based on previous 584 
experimental data8,10. The refined murine sepsis model, augmenting S. aureus sepsis with PG, 585 
increased reproducibility and decreased the spread of results. Revised power calculations (80% 586 
power; 95% confidence) permitted comparisons with 5 animals per group (n=5) for both weight 587 
loss (10% difference) and liver CFU (2 log difference). Animal experiments were not blinded but 588 
to reduce bias, selected experiments were performed by different team researchers. Mice were 589 
randomly selected for experimental or control groups and kept in separate cages throughout the 590 
experiment. In instances of unexpected death in animals which had otherwise been showing 591 
normal health, animals were excluded from analysis as per pre-established criteria. All statistical 592 
tests were appropriate for the type of data obtained. For zebrafish embryo survival experiments, 593 
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the Kaplan-Meier method was employed. Comparison between survival curves was made using 594 
the log-rank (Mantel Cox) test. For bacterial count comparison, skin lesion size or clinical arthritis 595 
severity in murine experiments, the Mann-Whitney U and Wilcoxson signed rank tests were used 596 
for comparison of unpaired and paired data, respectively. For comparison of two or more 597 
independent samples (parametric) a one-ǁĂǇ EKs ǁĂƐ ƵƐĞĚ ǁŝƚŚ dƵŬĞǇ ?Ɛ ŵƵůƚŝƉůĞ598 
comparison test. A two-way repeated measurements ANOVA compared pHrodo and OxyBURST 599 
data as shown and the CFU quantification in neutrophils. For macrophage assays, a 2-way ANOVA 600 
with Tukey ?Ɛ ŵƵůƚŝƉůĞ ĐŽŵƉĂƌŝƐŽŶ ƉŽƐƚ-test was used between the first two time-points. To 601 
compare the number of intracellular bacteria without and with PGN at all other time-points in 602 
the macrophage assays, a paired t-test was used. Statistical analysis was performed using Prism 603 
version 6.0 (GraphPad) and P < 0.05 was considered significant. Individual P values are reported. 604 
Multinomial probability was calculated to compare the expected frequency of outcomes with 605 
observed outcomes for strain ratios within individual abscesses in murine liver. 606 
 607 
Data availability 608 
The data supporting the findings of this study are available within the paper and its 609 
Supplementary Information.  610 
  611 
 26 
 612 
1. Isolauri, E., Kirjavainen, P. V. & Salminen, S. Probiotics: a role in the treatment of intestinal 613 
infection and inflammation? Gut 50, iii54-iii59 (2002). 614 
2. Grice, E. A. & Segre, J. A. The skin microbiome. Nat. Rev. Microbiol. 9, 244 ?253 (2011). 615 
3. Grice, E. A. et al. Topographical and Temporal Diversity of the Human Skin Microbiome. 616 
Science 324, 1190 ?1192 (2009). 617 
4. Naber, C. K. Staphylococcus aureus Bacteremia: Epidemiology, Pathophysiology, and 618 
Management Strategies. Clin. Infect. Dis. 48, S231 ?S237 (2009). 619 
5. Naik, S. et al. Commensal-dendritic-cell interaction specifies a unique protective skin 620 
immune signature. Nature 520, 104 ?108 (2015). 621 
6. Ramsey, M. M., Freire, M. O., Gabrilska, R. A., Rumbaugh, K. P. & Lemon, K. P. 622 
Staphylococcus aureus Shifts toward Commensalism in Response to Corynebacterium 623 
Species. Front. Microbiol. 7, 1230 (2016). 624 
7. Lo, C.-W., Lai, Y.-K., Liu, Y.-T., Gallo, R. L. & Huang, C.-M. Staphylococcus aureus Hijacks a 625 
^ŬŝŶŽŵŵĞŶƐĂůƚŽ/ŶƚĞŶƐŝĨǇ/ƚƐsŝƌƵůĞŶĐĞ P/ŵŵƵŶŝǌĂƚŝŽŶdĂƌŐĞƚŝŶŐɴ-Hemolysin and CAMP 626 
Factor. J. Invest. Dermatol. 131, 401 ?409 (2011). 627 
8. McVicker, G. et al. Clonal Expansion during Staphylococcus aureus Infection Dynamics 628 
Reveals the Effect of Antibiotic Intervention. PLoS Pathog. 10, e1003959 (2014). 629 
9. Prajsnar, T. K. et al. A privileged intraphagocyte niche is responsible for disseminated 630 
infection of Staphylococcus aureus in a zebrafish model. Cell. Microbiol. 14, 1600 ?1619 631 
(2012). 632 
 27 
10. Prajsnar, T. K., Cunliffe, V. T., Foster, S. J. & Renshaw, S. A. A novel vertebrate model of 633 
Staphylococcus aureus infection reveals phagocyte-dependent resistance of zebrafish to 634 
non-host specialized pathogens. Cell. Microbiol. 10, 2312 ?2325 (2008). 635 
11. Horsburgh, M. J., Wiltshire, M. D., Crossley, H., Ingham, E. & Foster, S. J. PheP, a Putative 636 
Amino Acid Permease of Staphylococcus aureus, Contributes to Survival In Vivo and during 637 
Starvation. Infect. Immun. 72, 3073 ?3076 (2004). 638 
12. Bera, A., Biswas, R., Herbert, S. & Götz, F. The presence of peptidoglycan O-639 
acetyltransferase in various staphylococcal species correlates with lysozyme resistance and 640 
pathogenicity. Infect. Immun. 74, 4598 ?4604 (2006). 641 
13. Cheng, A. G. et al. Contribution of Coagulases towards Staphylococcus aureus Disease and 642 
Protective Immunity. PLoS Pathog. 6, (2010). 643 
14. Grice, E. A. et al. A diversity profile of the human skin microbiota. Genome Res. 18, 1043 ?644 
1050 (2008). 645 
15. Sherertz, R. J. et al. Three-year experience with sonicated vascular catheter cultures in a 646 
clinical microbiology laboratory. J. Clin. Microbiol. 28, 76 ?82 (1990). 647 
16. Sorbara, M. T. & Philpott, D. J. Peptidoglycan: a critical activator of the mammalian immune 648 
system during infection and homeostasis. Immunol. Rev. 243, 40 ?60 (2011). 649 
17. Wheeler, R., Chevalier, G., Eberl, G. & Gomperts Boneca, I. The biology of bacterial 650 
peptidoglycans and their impact on host immunity and physiology. Cell. Microbiol. 16, 651 
1014 ?1023 (2014). 652 
18. Baba, T., Bae, T., Schneewind, O., Takeuchi, F. & Hiramatsu, K. Genome sequence of 653 
Staphylococcus aureus strain Newman and comparative analysis of staphylococcal 654 
 28 
genomes: polymorphism and evolution of two major pathogenicity islands. J. Bacteriol. 190, 655 
300 ?310 (2008). 656 
19. Surewaard, B. G. J. et al. Identification and treatment of the Staphylococcus aureus 657 
reservoir in vivo. J. Exp. Med. 213, 1141 ?1151 (2016). 658 
20. Thammavongsa, V., Missiakas, D. M. & Schneewind, O. Staphylococcus aureus degrades 659 
neutrophil extracellular traps to promote immune cell death. Science 342, 863 ?866 (2013). 660 
21. Wang, R. et al. Identification of novel cytolytic peptides as key virulence determinants for 661 
community-associated MRSA. Nat. Med. 13, 1510 ?1514 (2007). 662 
22. Elek, S. D. & Conen, P. E. The virulence of Staphylococcus pyogenes for man; a study of the 663 
problems of wound infection. Br. J. Exp. Pathol. 38, 573 ?586 (1957). 664 
23. Schleifer, K. H. & Kandler, O. Peptidoglycan types of bacterial cell walls and their taxonomic 665 
implications. Bacteriol. Rev. 36, 407 ?477 (1972). 666 
24. Hashimoto, M. et al. Lipoprotein is a predominant Toll-like receptor 2 ligand in 667 
Staphylococcus aureus cell wall components. Int. Immunol. 18, 355 ?362 (2006). 668 
25. Verdrengh, M. & Tarkowski, A. Role of neutrophils in experimental septicemia and septic 669 
arthritis induced by Staphylococcus aureus. Infect. Immun. 65, 2517 ?2521 (1997). 670 
26. Rigby, K. M. & DeLeo, F. R. Neutrophils in innate host defense against Staphylococcus 671 
aureus infections. Semin. Immunopathol. 34, 237 ?259 (2012). 672 
27. Heyworth, P. G., Cross, A. R. & Curnutte, J. T. Chronic granulomatous disease. Curr. Opin. 673 
Immunol. 15, 578 ?584 (2003). 674 
28. Zeng, Z. et al. CRIg Functions as a Macrophage Pattern Recognition Receptor to Directly 675 
Bind and Capture Blood-Borne Gram-Positive Bacteria. Cell Host Microbe 20, 99 ?106 (2016). 676 
 29 
29. Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances 677 
systemic innate immunity. Nat. Med. 16, 228 ?231 (2010). 678 
30. Gauguet, S. et al. Intestinal microbiota of mice influences resistance to Staphylococcus 679 
aureus pneumonia. Infect. Immun. (2015). doi:10.1128/IAI.00037-15 680 
31. Stoll, H., Dengjel, J., Nerz, C. & Götz, F. Staphylococcus aureus Deficient in Lipidation of 681 
Prelipoproteins Is Attenuated in Growth and Immune Activation. Infect. Immun. 73, 2411 ?682 
2423 (2005). 683 
32. Chamaillard, M. et al. An essential role for NOD1 in host recognition of bacterial 684 
peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4, 702 ?707 (2003). 685 
33. Wolf, A. J. et al. Hexokinase Is an Innate Immune Receptor for the Detection of Bacterial 686 
Peptidoglycan. Cell 166, 624 ?636 (2016). 687 
34. Pollock, J. D. et al. Mouse model of X-linked chronic granulomatous disease, an inherited 688 
defect in phagocyte superoxide production. Nat. Genet. 9, 202 ?209 (1995). 689 
35. Boyle, J. P., Parkhouse, R. & Monie, T. P. Insights into the molecular basis of the NOD2 690 
signalling pathway. Open Biol. 4, (2014). 691 
36. Philpott, D. J., Sorbara, M. T., Robertson, S. J., Croitoru, K. & Girardin, S. E. NOD proteins: 692 
regulators of inflammation in health and disease. Nat. Rev. Immunol. 14, 9 ?23 (2014). 693 
37. Korgaonkar, A., Trivedi, U., Rumbaugh, K. P. & Whiteley, M. Community surveillance 694 
enhances Pseudomonas aeruginosa virulence during polymicrobial infection. Proc. Natl. 695 
Acad. Sci. 110, 1059 ?1064 (2013). 696 
 30 
38. Horsburgh, M. J. et al. SigmaB Modulates Virulence Determinant Expression and Stress 697 
Resistance: Characterization of a Functional rsbU Strain Derived from Staphylococcus 698 
aureus 8325-4. J. Bacteriol. 184, 5457 ?5467 (2002). 699 
39. Mainiero, M. et al. Differential Target Gene Activation by the Staphylococcus aureus Two-700 
Component System saeRS. J. Bacteriol. 192, 613 ?623 (2010). 701 
40. Duthie, E. S. & Lorenz, L. L. Staphylococcal Coagulase: Mode of Action and Antigenicity. J. 702 
Gen. Microbiol. 6, 95 ?107 (1952). 703 
41. Pang, Y. Y. et al. agr-Dependent interactions of Staphylococcus aureus USA300 with human 704 
polymorphonuclear neutrophils. J. Innate Immun. 2, 546 ?559 (2010). 705 
42. Surewaard, B. G. J. et al. Inactivation of Staphylococcal Phenol Soluble Modulins by Serum 706 
Lipoprotein Particles. PLOS Pathog 8, e1002606 (2012). 707 
43. Fey, P. D. et al. A Genetic Resource for Rapid and Comprehensive Phenotype Screening of 708 
Nonessential Staphylococcus aureus Genes. mBio 4, e00537-12 (2013). 709 
44. Bremell, T. et al. Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. 710 
Arthritis Rheum. 33, 1739 ?1744 (1990). 711 
45. Modun, B. J., Cockayne, A., Finch, R. & Williams, P. The Staphylococcus aureus and 712 
Staphylococcus epidermidis transferrin-binding proteins are expressed in vivo during 713 
infection. Microbiology 144, 1005 ?1012 (1998). 714 
46. Hasenberg, A. et al. Catchup: a mouse model for imaging-based tracking and modulation of 715 
neutrophil granulocytes. Nat. Methods 12, 445 ?452 (2015). 716 
47. Gomez de Agüero, M. et al. The maternal microbiota drives early postnatal innate immune 717 
development. Science 351, 1296 ?1302 (2016). 718 
 31 
48. Nieto, C. & Espinosa, M. Construction of the mobilizable plasmid pMV158GFP, a derivative 719 
of pMV158 that carries the gene encoding the green fluorescent protein. Plasmid 49, 281 ?720 
285 (2003). 721 
49. Cheng, A. G. et al. Genetic requirements for Staphylococcus aureus abscess formation and 722 
persistence in host tissues. FASEB J. 23, 3393 ?3404 (2009). 723 
50. Turner, R. D. et al. Peptidoglycan architecture can specify division planes in Staphylococcus 724 
aureus. Nat. Commun. 1, 26 (2010). 725 
51. Sabroe, I., Williams, T. J., Hébert, C. A. & Collins, P. D. Chemoattractant cross-726 
desensitization of the human neutrophil IL-8 receptor involves receptor internalization and 727 
differential receptor subtype regulation. J. Immunol. 158, 1361 ?1369 (1997). 728 
52. Dockrell, D. H., Lee, M., Lynch, D. H. & Read, R. C. Immune-mediated phagocytosis and 729 
killing of Streptococcus pneumoniae are associated with direct and bystander macrophage 730 
apoptosis. J. Infect. Dis. 184, 713 ?722 (2001). 731 
53. Ali, A. et al. CTLA4 Immunoglobulin but Not Anti-Tumor Necrosis Factor Therapy Promotes 732 
Staphylococcal Septic Arthritis in Mice. J. Infect. Dis. 212, 1308 ?1316 (2015). 733 
54. Kwiecinski, J., Jin, T. & Josefsson, E. Surface proteins of Staphylococcus aureus play an 734 
important role in experimental skin infection. APMIS 122, 1240 ?1250 (2014). 735 
55. Wong, C. H. Y., Jenne, C. N., Lee, W.-Y., Léger, C. & Kubes, P. Functional Innervation of 736 
Hepatic iNKT Cells Is Immunosuppressive Following Stroke. Science 334, 101 ?105 (2011). 737 
56. Wilson, R. et al. Protection against Streptococcus pneumoniae lung infection after 738 
nasopharyngeal colonization requires both humoral and cellular immune responses. 739 
Mucosal Immunol. 8, 627 ?639 (2015). 740 
 32 
57. Nusslein-Volhard, C. & Dahm, R. Zebrafish. A Practical Approach. (New York: Oxford 741 
University Press, 2002). 742 
 743 
